Proactive Investors - Run By Investors For Investors

Biohaven Pharmaceutical stock falls on $300M offering as it kills intense investor speculation of a sale

The Connecticut-based biotech will use the proceeds together with existing cash to advance its promising migraine drug pipeline
An executive with a headache
The company is gearing up to launch a migraine product under consideration for FDA approval

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) tumbled Tuesday after news of a mixed shelf registration and $300 million share offering killed intense speculation that the migraine drug developer was exploring a sale.

The New Haven, Connecticut-based clinical-stage biopharmaceutical company took the market by surprise by revealing that in addition to the $300 million offering, it will grant the underwriters a 30-day option to buy an additional $45 million in shares at the public offering price.

Investors who had sent shares of Biohaven climbing since April while pinning their hopes on a lucrative sale, turned sour on the biotech on Tuesday sending shares plunging over 25% to $42.95.

READ: Breakthrough test predicts which HIV patients will respond to CytoDyn's leronlimab as a monotherapy

In April, Bloomberg reported that the drug maker was exploring options including a possible sale of the company after attracting interest from potential bidders.

Biohaven says it plans to use the proceeds from the offering, together with existing cash, to advance its pipeline.

The company is gearing up to launch a migraine product which is under consideration for approval at the US Food and Drug Administration.

Despite the stock plunge, Canaccord analyst Sumant Kulkarni continues to see potential in Biohaven’s rimegepant migrane product. According to Kulkarni has a Buy rating and $89 price target on the biotech.

Biohaven is also doing research in Alzheimer’s disease, inflammation and neurodegeneration. Bloomberg reported the company may be attractive to buyers in part because it’s one of the few still focused on this line of research.

Goldman Sachs and Piper Jaffray are acting as joint book-runners for the offering.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

View full PROAC profile View Profile

Proactiveinvestors Timeline

Related Articles

June 26 2019
Speaking in April, Next’s chief executive Tim Dyson said the company had “lots of scope” for acquisitions in the coming year
July 05 2019
With over 1.6 billion people globally learning the language, Lingo has developed a SaaS platform that seamlessly blends education and technology
March 22 2019
The healthcare-focused advisory group boasts good levels of forward bookings thanks to several new business wins at the beginning of 2019
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use